TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03094429: An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With C

Sponsor: SyneuRx International (Taiwan) Corp · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 287 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,147,520

Rescue Site Savings

+$9,987,896

Unlock Full NCT03094429 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03094429 Rescue Dossier →